𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparison of p53 gene abnormalities in bilateral and unilateral breast cancer

✍ Scribed by Takayuki Kinoshita; Masakazu Ueda; Kohji Enomoto; Tadashi Ikeda; Kiyoshi Kikuchi; Seiichiro Ishii; Masaki Kitajima

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
563 KB
Volume
76
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Background. The results of recent studies have suggested that p53 gene abnormalities are associated with carcinogenesis in several neoplasms. It is believed that bilateral breast carcinomas develop as a result of a different carcinogenetic mechanism and genetic environment from those of unilateral lesions.

Methods. p53 Gene abnormalities in bilateral primary breast cancer were detected by polymerase chain reaction-single strand comformation polymorphism (PCR-SSCP) analysis. A total of 76 paraffin embedded tissue specimens from 38 patients with bilateral primary breast cancer were examined, and 62 patients with unilateral breast cancer were analyzed as control subjects. The bilateral tumors were defined as primary, based on clinical parameters and the presence of an intraductal component. There were 13 patients with synchronous bilateral breast cancer and 25 with metachronous bilateral breast cancer.

Results. p53 Gene abnormalities were detected in 50% of the bilateral and 25.8% of the unilateral cases, and the difference was significant ( P < 0.01, chi-square test). Abnormalities were detected in 56% of the metachronous cases, representing a much higher incidence than that of the unilateral cases (P < 0.001, chi-square test). The incidence of p53 gene abnormalities in the first and second tumors of the metachronous cases was 44% and 68%, respectively. The percentage of patients with a p53 gene abnormality and positive family history was higher for those with bilateral than with unilateral breast cancer ( P < 0.01, chi-square test).

Conclusion. These findings indicate that the genetic

From the

πŸ“œ SIMILAR VOLUMES

Relationship between p53 gene abnormalit
Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis
✍ Ram Seshadri; Anthony S.-Y. Leong; Kieran McCaul; Frank A. Firgaira; Vittal Setl πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 French βš– 757 KB

The prognostic significance of p53 gene abnormalities was investigated in 9 I9 primary breast-cancer patients. p53 expression and tumour-cell proliferation fraction determined by MIB-I count, p53 exon 5 and 6 mutations and HER-Z/neu oncogene amplification were detected by immunohistochemistry, PCR-S

Mutations of the p53 gene in male breast
Mutations of the p53 gene in male breast cancer
✍ Agnaldo Anelli; Tǎnia F. M. Anelli; Bruce Youngson; Paul P. Rosen; Patrick I. Bo πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 609 KB
Polymorphisms in drug metabolism genes,
Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer
✍ Beth O. Van Emburgh; Jennifer J. Hu; Edward A. Levine; Libyadda J. Mosley; L. Do πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 146 KB πŸ‘ 1 views

## Abstract Polymorphisms in phase I and phase II enzymes may enhance the occurrence of mutations at critical tumor suppressor genes, such as __p53__, and increase breast cancer risk by either increasing the activation or detoxification of carcinogens and/or endogenous estrogens. We analyzed polymo

Abnormal p53 expression is rare in clini
Abnormal p53 expression is rare in clinically localized human prostate cancer: Comparison between immunohistochemical and molecular detection of p53 mutations
✍ Mottaz, Alain E.; Markwalder, Regula; Fey, Martin F.; Klima, Irena; Merz, Vincen πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 180 KB πŸ‘ 3 views

## BACKGROUND. We assessed the frequency and molecular basis of p53 mutations in clinically localized prostatic adenocarcinoma. METHODS. Prostate specimens were examined from 100 patients with clinically localized prostatic adenocarcinoma and 13 patients with benign prostatic hyperplasia (BPH). Mu